Original Research

JCP
Esketamine Nasal Spray and Adverse Events Over Time
Original Research

September 19, 2022

This study looked at the occurrence and severity of adverse events over time with esketamine nasal spray in MDD patients also receiving an oral antidepressant.
, , , et al
PCC
Psychological Impact of the COVID-19 on Outpatients With Psychiatric Illness
Original Research

September 15, 2022

This study explored the psychological impact of the COVID-19 pandemic and associated lockdown on outpatients with psychiatric illness.
, , , et al
PCC
Societal Outcomes in US Veterans with Schizophrenia Relapse
Original Research

September 13, 2022

This study evaluated societal outcomes including unemployment and homelessness among US veterans with schizophrenia with a history of relapse.
, , , et al
PCC
Personality Traits and Nomophobia
Original Research

September 13, 2022

Nomophobia is the fear and anxiety associated with being without digital devices. This study assessed nomophobia and its relationship with personality traits and other sociodemographic factors.
, , , et al
JCP
Parental Mental Illness and Child Injury Risk
Original Research

September 12, 2022

Childhood injury is associated with parental serious mental illness (SMI). This study investigated whether the associations between parental SMI and child injury vary according to which parent had an...
, , , et al
JCP
Intravenous Ketamine for Treatment-Resistant Depression
Original Research

September 12, 2022

The clinical effectiveness of ketamine for suicidal ideation and treatment-resistant depression outside of controlled clinical trials is unclear. This article reports clinical outcomes of a large cohort treated with...
, , , et al
PCC
Young Adult Depression, Antidepressant Prescriptions, and Therapy Intensification in the US
Original Research

September 6, 2022

This study evaluated the temporal trend in young adult depression, prescription patterns of first- and second-line antidepressants, and factors influencing therapy intensification for depression stratified by sex.
, , , et al
JCP
Reasons for Switching Antipsychotic Treatments
Original Research

September 5, 2022

Based on prescription records and prescriber notes, almost half of antipsychotic switches were due to side effects, and women were especially likely to be switched due to intolerability or...
, , , et al
JCP
Machine Learning Prediction of Suicide Risk
Original Research

August 31, 2022

Suicide assessment prompted by prediction models may be intrusive to patients with no history of suicidality. This study examined if machine learning models identify patients with high suicide risk...
, , , et al
JCP
Impact of SUD on COVID-19 Outcomes
Original Research

August 29, 2022

Identifying risk factors that predispose individuals to negative COVID-19 outcomes is important. The current study examined the association between substance use disorders, psychiatric diagnosis, and COVID-19–related clinical outcomes.
, , , et al
JCP
Machine Learning Prediction of ECT Responses
Original Research

August 24, 2022

Predicting individual therapeutic outcomes would be clinically useful to help patients accept electroconvulsive therapy (ECT) for treating depression. This study sought to develop a prediction model for ECT response...
, , , et al
PCC
Burden of Psychiatric Disorders in Moyamoya Disease
Original Research

August 23, 2022

The objective of this study was to investigate psychiatric comorbidities and trends in patients with Moyamoya disease in the United States.
, , , et al
JCP
Omega-3 Fatty Acids for MDD With High Inflammation
Original Research

August 22, 2022

This study investigated whether dosage or inflammation levels affect response to omega-3s in MDD patients.
, , , et al
PCC
Suicide Methods of Depressed and Bipolar Individuals
Original Research

August 16, 2022

This study examined the prevalence of different methods of suicide and self-inflicted poisoning/injury in individuals with major depressive disorder or bipolar disorder.
, , , et al
JCP
Intravenous Scopolamine Versus Active Placebo in MDD
Original Research

August 15, 2022

Scopolamine, an agent commonly used for motion sickness, has shown promise in treating depression. This study measured its efficacy in major depressive disorder versus an active placebo comparator.
, , , et al
PCC
Computer Vision Syndrome, Insomnia, and Migraine
Original Research

August 11, 2022

This study assessed the correlation between computer vision syndrome, insomnia, and migraine, using stress as a mediating factor.
, , , et al
JCP
Remission of Psychotic Late-Life Depression Following ECT
Original Research

August 10, 2022

In this study, ECT was associated with a significantly higher remission rate in psychotic versus nonpsychotic late-life depression.
, , , et al
PCC
Substance Abuse and Metabolic Syndrome
Original Research

August 9, 2022

This study estimated the prevalence and predictors of metabolic syndrome among substance users in North India.
, , , et al
JCP
Faces Scales to Measure Anxiety and Anger
Original Research

August 8, 2022

Faces scales are used worldwide to assess pain. This study aimed to develop and evaluate measurement properties of faces scales to monitor the mental health symptoms of anxiety and...
, , , et al
JCP
Very Low-Level Transcranial Photobiomodulation for MDD
Original Research

August 8, 2022

Transcranial photobiomodulation may be efficacious for major depressive disorder, but the optimal dose is not known. Here, a very low dose was studied to establish a threshold for lack...
, , , et al
JCP
Cannabidiol for Treatment-Resistant Anxiety
Original Research

August 3, 2022

Treatment resistance affects nearly half of all young patients experiencing moderate-to-severe anxiety. This study investigated the safety and efficacy of cannabidiol for anxiety in young people who previously failed...
, , , et al
JCP
Tardive Dyskinesia and Long-Acting Injectable Antipsychotics
Original Research

August 3, 2022

This study compared spontaneous reporting of tardive dyskinesia with long-acting injectable versus oral antipsychotics.
, ,
JCP
Add-on Pramipexole for Schizophrenia
Original Research

August 1, 2022

Several small clinical trials have reported that the dopamine agonist pramipexole was beneficial in treating patients with schizophrenia. This 16-week, multicenter, double-blind, randomized, placebo-controlled study was conducted to test...
, , , et al
JCP
Depression Severity, Psychotic Depression, and Suicide Risk
Original Research

July 27, 2022

Depression is the strongest diagnostic predictor of suicide. This study investigated the role of depression severity in suicide risk by studying the predictive value of psychotic symptoms and depression...
, , , et al

Watch the New PsychCase360

Explore two real-world schizophrenia cases

Subscribe to read
more articles

Subscribe